BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab.

Allogene Therapeutics, Inc. today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:45 p.m. Pacific Time.

Dyadic International, Inc. today announces that its senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference in San Francisco.

Vericel Corporation today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 10:30 am PT / 1:30 pm ET , in San Francisco, California.

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

MMI ( Medical Microinstruments, Inc. ), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 9-12, 2023.

Orion Corporation announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amneal’s generic products in Orion territories.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced dosing of the first patient with type 2 diabetes in the Phase II portion of COVALENT-111 in the U.S.

NorthStar Medical Radioisotopes, LLC and Inhibrx, Inc. announced a collaboration to develop and produce novel radiopharmaceuticals for the treatment of cancer.